Immune-checkpoint inhibition for resectable non-small-cell lung cancer—Opportunities and challenges
G Mountzios, J Remon, LEL Hendriks… - Nature Reviews …, 2023 - nature.com
Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …
successfully used for several cancer types, including in patients with advanced-stage non …
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
YZ Li, SN Kong, YP Liu, Y Yang, HM Zhang - Journal of Clinical Medicine, 2023 - mdpi.com
More and more clinical trials have explored the role of liquid biopsy in the diagnosis and
treatment of EGFR-mutated NSCLC. In certain circumstances, liquid biopsy has unique …
treatment of EGFR-mutated NSCLC. In certain circumstances, liquid biopsy has unique …
A mulberry diels-alder-type adduct, Kuwanon M, triggers apoptosis and paraptosis of lung cancer cells through inducing endoplasmic reticulum stress
M Ma, X Luan, H Zheng, X Wang, S Wang… - International Journal of …, 2023 - mdpi.com
The mulberry tree (Morus alba) has been cultivated in China for thousands of years.
Mulberry Diels-Alder-type adducts (MDAAs) are characteristic constituents of the genus …
Mulberry Diels-Alder-type adducts (MDAAs) are characteristic constituents of the genus …
MicroRNA‑20a promotes non‑small cell lung cancer proliferation by upregulating PD‑L1 by targeting PTEN
J Gong, Y Shen, F Jiang, Y Wang, L Chu… - Oncology …, 2022 - spandidos-publications.com
Non‑small cell lung cancer (NSCLC) remains one of the most common malignant tumors
worldwide. The aim of the present study was to investigate the possibility of microRNA‑20a …
worldwide. The aim of the present study was to investigate the possibility of microRNA‑20a …
Synthesis and biological activity screening of newly synthesized trimethoxyphenyl-based analogues as potential anticancer agents
T Al-Warhi, M Abualnaja, OA Abu Ali, F Althobaiti… - Molecules, 2022 - mdpi.com
A group of novel trimethoxyphenyl (TMP)-based analogues were synthesized by varying the
azalactone ring of 2-(3, 4-dimethoxyphenyl)-4-(3, 4, 5-trimethoxybenzylidene) oxazolone 1 …
azalactone ring of 2-(3, 4-dimethoxyphenyl)-4-(3, 4, 5-trimethoxybenzylidene) oxazolone 1 …
[HTML][HTML] Challenges in the use of targeted therapies in non–small cell lung cancer
J Rivera-Concepcion, D Uprety… - Cancer Research and …, 2022 - ncbi.nlm.nih.gov
Precision oncology has fundamentally changed how we diagnose and treat cancer. In
recent years, there has been a significant change in the management of patients with …
recent years, there has been a significant change in the management of patients with …
Prediction of postoperative health-related quality of life among patients with metastatic spinal cord compression secondary to lung cancer
Y Fu, W Shi, J Zhao, X Cao, Y Cao, M Lei… - Frontiers in …, 2023 - frontiersin.org
Background Health-related quality of life (HRQoL) is a critical aspect of overall well-being for
patients with lung cancer, particularly those with metastatic spinal cord compression …
patients with lung cancer, particularly those with metastatic spinal cord compression …
Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant …
R Bei, M Benvenuto, C Focaccetti, S Fazi… - Journal of Translational …, 2022 - Springer
Malignant mesothelioma (MM) is a rare orphan aggressive neoplasia with low survival rates.
Among the other signaling pathways, ErbB receptors and Hh signaling are deregulated in …
Among the other signaling pathways, ErbB receptors and Hh signaling are deregulated in …
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC
JE Frampton - Targeted oncology, 2022 - Springer
Osimertinib (TAGRISSO®) is an orally administered, third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor that is approved for the adjuvant treatment of …
factor receptor (EGFR) tyrosine kinase inhibitor that is approved for the adjuvant treatment of …
Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer
L Liu, S Zhang, HY Yang, CH Zhou, Y Xiong… - Lipids in Health and …, 2024 - Springer
Background Studies have shown that integrating anlotinib with programmed death 1 (PD-
1)/programmed death-ligand 1 (PD-L1) inhibitors enhances survival rates among …
1)/programmed death-ligand 1 (PD-L1) inhibitors enhances survival rates among …